ChrisChrisW
- GSK (GSK) said that interim results from the phase 2 AZER-1 trial showed that patients with a certain type of rectal cancer given Jemperli (dostarlimab) showed a sustained complete clinical response rate at one year.
- Enrolled patients had stage II/III mismatch
